Cancer Immunology Reserch

Cancer Immunol Res. 2025 Jul 30. doi: 10.1158/2326-6066.CIR-24-0919. Online ahead of print. ABSTRACT Therapies using natural killer (NK) cells that express chimeric antigen receptors (CAR-NKs) have been successfully employed against hematological malignancies. However, solid tumors resist CAR NKs partly by enriching tumor microenvironments with ligands for NK cell inhibitory receptors. Although the NK inhibitory receptor … Read more

Cancer Immunol Res. 2025 Jul 18. doi: 10.1158/2326-6066.CIR-24-1146. Online ahead of print. ABSTRACT Tumor-associated macrophages (TAMs) are key regulators of tumor immunity. With advances in single-cell analyses, SPP1+ TAMs have been observed across multiple tumor sites. However, their clinical relevance and phenotypic characteristics in clear cell renal cell carcinoma (ccRCC) have not been comprehensively delineated. … Read more

Cancer Immunol Res. 2025 Jul 8. doi: 10.1158/2326-6066.CIR-24-0532. Online ahead of print. ABSTRACT Tyrosine kinase inhibitors (TKIs) are initially efficacious against anaplastic lymphoma kinase (ALK) fusion gene-positive lung adenocarcinoma (ALK+ LUAD), but acquired resistance inevitably occurs. Therefore, alternative treatment strategies are needed for TKI-resistant cases. Although the use of immune checkpoint inhibitors (ICIs) has improved … Read more

Cancer Immunol Res. 2025 Jul 8. doi: 10.1158/2326-6066.CIR-24-1285. Online ahead of print. ABSTRACT Vγ9Vδ2 (TCRVγ9+ TCRVδ2+) T cells are promising immunotherapeutic targets with effective antitumor properties in both in vitro and preclinical models of triple-negative breast cancer (TNBC). However, no information regarding their potential role in the context of human TNBC progression and response to … Read more

Cancer Immunol Res. 2025 Jul 2. doi: 10.1158/2326-6066.CIR-25-0103. Online ahead of print. ABSTRACT Tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) are major immune components of the tumor microenvironment, promoting tumor growth and limiting the efficacy of chemotherapy in almost all cancer indications. While Tregs are well known for their immune suppressive activity toward the … Read more

Cancer Immunol Res. 2025 Jul 2. doi: 10.1158/2326-6066.CIR-25-0034. Online ahead of print. ABSTRACT Dendritic cell (DC) based-vaccines remain the sole approved cancer vaccine. Despite their established safety and efficacy in numerous trials against cancers and infections, long-term clinical benefits have been modest. Most trials have employed DCs derived from blood monocytes (MoDC), but emerging evidence … Read more

Cancer Immunol Res. 2025 Jul 2;13(7):963. doi: 10.1158/2326-6066.CIR-13-7-WWR. NO ABSTRACT PMID:40598952 | DOI:10.1158/2326-6066.CIR-13-7-WWR

Cancer Immunol Res. 2025 Jul 1. doi: 10.1158/2326-6066.CIR-24-1144. Online ahead of print. ABSTRACT Cancer-associated fibroblasts (CAFs) play immunosuppressive roles in the tumor microenvironment (TME). Specifically, they reportedly act as physical barriers preventing immune cell infiltration. However, the spatial relationships between CAFs and cancer cells in antitumor immunity remain unknown. In this study, we established three-dimensional … Read more

Cancer Immunol Res. 2025 Jul 1. doi: 10.1158/2326-6066.CIR-24-1109. Online ahead of print. ABSTRACT The blood T cell receptor (TCR) repertoire broadly reflects current and lifetime immune responses against infectious pathogens and cancer, but the circulating T cell repertoire remains a largely untapped resource for cancer biomarker studies due to repertoire complexity and limited profiling data. … Read more

Cancer Immunol Res. 2025 Jun 27. doi: 10.1158/2326-6066.CIR-24-1313. Online ahead of print. ABSTRACT Anti-BCMA CAR-T cell therapy has revolutionized the prognosis of relapsed / refractory multiple myeloma patients. Regrettably, despite unprecedented overall response rates achieved with this approach, most patients eventually relapse. One of the primary reasons for this is the complete loss or reduced … Read more